Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Aspira Women's Health Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

Aspira Women's Health Inc.

AWHLOTCEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Conditions. On November 14, 2025, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and nine months ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No.…

Filed Nov 14, 2025Accepted Nov 14, 2025, 8:54 AM ESTCIK 926617Accession 0000926617-25-000004
View company →Permanent SEC source ↗
Share

Company context

We are dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.

Current securities

AWHLOTC · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementJul 15, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 7, 2026
  4. D filingJun 22, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 22, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Conditions. On November 14, 2025, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and nine months ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description ───────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release issued by Aspira Women’s Health Inc. on November 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Filed exhibits (1)
EX-99.1 (by filename) awhl-20251114xex99d1.htm

EX-99.1 2 awhl-20251114xex99d1.htm EX-99.1 Exhibit 99.1 Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update AUSTIN, Texas, November 14, 2025 (GLOBE NEWSWIRE) - Aspira Women’s Health Inc. (“Aspira”) (OTCQX: AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025. September Q3 Highlights: Aspira reported relatively flat total product revenues of $2.3 million for the third quarters of 2025 and 2024. The average unit price per test (“AUP”) grew 7.0% year-over-year for the commercial product portfolio, comprised of non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus™ and OvaWatch℠. Comparative product revenue stability was achieved despite the significant reset of Aspira’s business model and market strategies beginning in the first quarter of 2025, with continuing substantial changes well into the third quarter of 2025. In this comprehensive re-focus of our strategy, commercial model, and resources, Aspira heav…

Open exhibit ↗